Assignee
PHIO PHARM CORP
US·22 granted patents·9 pending applications·243 citations·filing 2014–2022
Top patents by PatentIndex Score
31 records- 0198US10633654B2Modified RNAi polynucleotides and uses thereofPHIO PHARM CORP·Filed 2018·Granted Apr 28, 2020·32 cites·20 claims
- 0298US10479992B2RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityPHIO PHARM CORP·Filed 2017·Granted Nov 19, 2019·27 cites·20 claims
- 0397US10913948B2RNA interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2018·Granted Feb 9, 2021·21 cites·7 claims
- 0497US10774330B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2015·Granted Sep 15, 2020·15 cites·19 claims
- 0597US10662430B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2018·Granted May 26, 2020·14 cites·19 claims
- 0696US11667915B2RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionalityPHIO PHARM CORP·Filed 2019·Granted Jun 6, 2023·10 cites·20 claims
- 0796US10240149B2Reduced size self-delivering RNAi compoundsPHIO PHARM CORP·Filed 2015·Granted Mar 26, 2019·23 cites·21 claims
- 0894US11118178B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2019·Granted Sep 14, 2021·8 cites·10 claims
- 0994US10876119B2Reduced size self-delivering RNAI compoundsPHIO PHARM CORP·Filed 2018·Granted Dec 29, 2020·7 cites·20 claims
- 1094US10815485B2RNA interference in skin indicationsPHIO PHARM CORP·Filed 2018·Granted Oct 27, 2020·8 cites·5 claims
- 1193US11584933B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2020·Granted Feb 21, 2023·2 cites·20 claims
- 1292US10900039B2Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1PHIO PHARM CORP·Filed 2015·Granted Jan 26, 2021·7 cites·4 claims
- 1391US11001845B2Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PHIO PHARM CORP·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 1490US11396654B2Neutral nanotransportersPHIO PHARM CORP·Filed 2018·Granted Jul 26, 2022·4 cites·19 claims
- 1587US11926828B2Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1PHIO PHARM CORP·Filed 2021·Granted Mar 12, 2024·1 cites·12 claims
- 1687US10300027B2Effective sensitizing dose of a gelled immunomodulating topical compositionPHIO PHARM CORP·Filed 2014·Granted May 28, 2019·19 cites·12 claims
- 1786US11254940B2Inhibition of MAP4K4 through RNAiPHIO PHARM CORP·Filed 2015·Granted Feb 22, 2022·5 cites·9 claims
- 1886US11021707B2Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAPHIO PHARM CORP·Filed 2016·Granted Jun 1, 2021·7 cites·19 claims
- 1984US10934550B2Immunotherapy of cancerPHIO PHARM CORP·Filed 2014·Granted Mar 2, 2021·12 cites·18 claims
- 2084US10808247B2Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approachPHIO PHARM CORP·Filed 2016·Granted Oct 20, 2020·9 cites·14 claims
- 2183US11279934B2Methods for treating cancer using nucleic acids targeting MDM2 or MYCNPHIO PHARM CORP·Filed 2015·Granted Mar 22, 2022·5 cites·8 claims
- 2277US2021147849A1Reduced size self-delivering rnai compoundsPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 2372US2021261968A1Rna interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 2465US2019218557A1Inhibition of pcsk9 through rnaiPHIO PHARM CORP·Filed 2018·Application pending·0 cites
- 2557US2024301430A1Chemically modified oligonucleotidesPHIO PHARM CORP·Filed 2022·Application pending·0 cites
- 2655US2023089478A1Chemically modified oligonucleotides with improved systemic deliveryPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 2752US2021348166A1Immunotherapy of cancerPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 2852US2020101028A1Effective sensitizing dose of a gelled immunomodulating topical compositionPHIO PHARM CORP·Filed 2019·Application pending·0 cites
- 2950US2023002766A1Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapyPHIO PHARM CORP·Filed 2020·Application pending·0 cites
- 3044US12544344B2Topical delivery of nucleic acid compoundsPHIO PHARM CORP·Filed 2018·Granted Feb 10, 2026·0 cites·9 claims
- 3137US2020215113A1Chemically modified oligonucleotidesPHIO PHARM CORP·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PHIO PHARM CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →